MRI 3D UTE Hyper-Cones & ZTE for PET/MR Lung Attenuation Correction & for Lung Diagnostic Imaging

NCT ID: NCT03562806

Last Updated: 2022-05-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-23

Study Completion Date

2021-03-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

MRI 3D UTE Hyper-Cones \& ZTE for PET/MR lung attenuation correction \& for lung diagnostic imaging

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective is to clinically test the feasibility of 3D UTE Hyper-Cones \& ZTE in capturing lung density of patients with lung diseases at reasonable clinical imaging times compared to standard MR lung protocols (LAVA-Flex, PROPELLER). Secondly, we want to investigate if Hyper-Cones \& ZTE can be used for lung imaging such as vessels and air-pathways, oncological patients, lung nodules and lung infiltration \& parenchyma pathophysiology such as chronic obstructive pulmonary disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PET/MR (single arm)

PET and MR sequence acquisition on SIGNA PET/MR device

Group Type EXPERIMENTAL

PET/MR image acquisition

Intervention Type DIAGNOSTIC_TEST

Acquisition of PET and MR sequences on SIGNA PET/MR device.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PET/MR image acquisition

Acquisition of PET and MR sequences on SIGNA PET/MR device.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* informed consent and signature
* clinical PET/CT planned and performed at Wagi site in Schlieren
* male or female patients
* from 18 to 80 years of age.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martin Huellner, M.D.

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Zürich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Zurich, Department of Nuclear Medicine

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-00899

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MPDL3280A-imaging-IST-UMCG
NCT02453984 ACTIVE_NOT_RECRUITING NA
MPDL3280A-treatment-IST-UMCG
NCT02478099 ACTIVE_NOT_RECRUITING PHASE2